These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21393298)

  • 1. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
    Deedwania PC; Ahmed MI; Feller MA; Aban IB; Love TE; Pitt B; Ahmed A
    Eur J Heart Fail; 2011 May; 13(5):551-9. PubMed ID: 21393298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
    Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Olivier A; Girerd N; Michel JB; Ketelslegers JM; Fay R; Vincent J; Bramlage P; Pitt B; Zannad F; Rossignol P;
    Int J Cardiol; 2017 Aug; 241():344-350. PubMed ID: 28284500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction.
    Ahmed A; Pitt B
    Am J Cardiol; 2009 May; 103(10):1374-80. PubMed ID: 19427431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
    Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C; Ahmed A; Fay R; Angioi M; Filippatos G; Vincent J; Pitt B; Zannad F;
    Eur J Heart Fail; 2009 Nov; 11(11):1099-105. PubMed ID: 19875410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
    J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
    Iqbal J; Fay R; Adlam D; Squire I; Parviz Y; Gunn J; Pitt B; Zannad F
    Eur J Heart Fail; 2014 Jun; 16(6):685-91. PubMed ID: 24706498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 14. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
    Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.
    Stienen S; Rossignol P; Barros A; Girerd N; Pitt B; Zannad F; Ferreira JP
    Clin Res Cardiol; 2020 Feb; 109(2):194-204. PubMed ID: 31250134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone.
    Kampourides N; Tziakas D; Chalikias G; Papazoglou D; Maltezos E; Symeonides D; Konstantinides S
    Am J Cardiol; 2012 Oct; 110(8):1085-91. PubMed ID: 22742718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
    Pitt B; Ahmed A; Love TE; Krum H; Nicolau J; Cardoso JS; Parkhomenko A; Aschermann M; Corbalán R; Solomon H; Shi H; Zannad F
    Hypertension; 2008 Aug; 52(2):271-8. PubMed ID: 18559720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
    Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
    Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial.
    Pitt B; Zannad F; Gheorghiade M; Martínez F; Love TE; Daniel C; Ahmed A
    Int J Cardiol; 2010 Sep; 143(3):309-16. PubMed ID: 19371959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.